Clinical trials recruiting in Zhejiang, China

Phase breakdown

Conditions recruiting in Zhejiang, China

Recruiting trials in Zhejiang, China

• A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
  NCT06152107 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
  NCT07330544 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JMT203 in Patients With Cancer Cachexia
  NCT06868849 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
  NCT07066657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
  NCT07455188 · Phase: Not specified · Ages: 18 Years and older · Sex: Female
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Bone Management in Pregnancy Outcomes in Epilepsy
  NCT07651709 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female
• China Colorectal Cancer Screening Trial 1 (C-Cost1)
  NCT07090291 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 74 Years · Sex: All (male and female)
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
  NCT06809764 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
  NCT05899608 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Effectiveness of Artificial IntelliGence-Driven Single-LEad Long-TerM Electrocardiograms MonItoring in Detecting New-Diagnosed Atrial FIbrillation
  NCT06842147 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female)
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
  NCT07492342 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• JMT106 Injection in the Treatment of Advanced Solid Tumors
  NCT07275073 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Lecanemab for Early Onset Familial Alzheimer's Disease
  NCT06883019 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
  NCT05712200 · Phase: Phase 3 · Ages: 65 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Zhejiang, China?

20 recruiting trials have at least one study site in Zhejiang, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.